Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: JamesK who wrote (51951)	6/3/2022 9:39:15 PM
From: A.J. Mullen	Read Replies (1) \| Respond to of 52153

I sold half my ALNY in June of last year and wish I'd chosen one of several others). Being in revenue (not profit), it's lost less than many. It's now has 1.5 x standard weight in my portfolio. I'm unaware of BBIO's connection. Immunic (IMUX) was holding up very well in the current environment given it is revenue-free. It dropped nearly 50% on announcing results in ulcerative colitis. I hold a small position and have not sold on the news, consoling myself that now their meagre cash need not be spread so far. Ashley